Actinogen Medical Ltd (ACW)
20mins delayed
Movement
1 Year Return
Actinogen Medical Ltd Chart
| Share price | |
| Last | |
| Change | |
| Volume | |
| Turnover | |
| Market Cap | $31.92 million |
| Today's Movement | |
| Prev. Close | |
| Open | |
| Day Range | - |
| VWAP | |
| Historical Stats | |
| 52w Range | - |
| 4w Avg Volume | |
| 4w Avg Turnover | |
| (delayed) | |
ACW Statistics
27 November
1,454 / 2,246
ASX Size Rank
1yr Return
vs Sector (1yr)
-59.43%
vs ASX 200 (1yr)
-43.96%
$31.92 million
Market Cap
Share Issue
1.45 billion
All Ords (%)
N/A
Short Sold
0%
Current Fundamentals
27 November
N/A
PE Ratio
EPS ($)
-0.005
Earnings Yield
-21.82%
NTA ($)
0.01
0.00%
Dividend Yield
DPS ($)
-
Gross Div. Yield
-
Gross DPS ($)
-
Company Overview
Actinogen Medical Limited (ACW, formerly Actinogen Limited) is an ASX-listed biotechnology company developing innovative treatments for Alzheimer's disease and the cognitive decline associated with neurodegenerative diseases and metabolic diseases, like Type 2 diabetes. It focusses on the development of Xanamem, a novel treatment for Alzheimer's disease and the cognitive deficiency associated with other neurological and metabolic diseases within Australia.
Former Names
Actinogen Limited (ACW), 17/11/2015
Upcoming Calendar
| 18 Feb 2021 | Report (Interim) |
| 25 Aug 2021 | Report (Prelim) |
| 25 Aug 2021 | Report (Annual) |
| 25 Oct 2021 | Report (Annual) |
Dividend History
| Ex-Date | Amount | Franking | Type | Payable |
|---|---|---|---|---|
| No dividends paid in the last 5 years | ||||
See Upcoming Dividends for all ASX companies.
Announcements
| Date | Heading | Pages | File Size | Time |
|---|---|---|---|---|
Announcements provided by
Broker Consensus
The buy, hold and sell recommendations from Australian stockbroking firms are combined to form a "broker consensus". See the Consensus Data posts for more information.
ACW is not covered by a major broker,
or data from most recent compilation was omitted due
to not meeting QA guidelines.
Directors & Management
| Name | Title | Since | Bio |
|---|---|---|---|
| Dr George Morstyn | Non-Executive Director | Dec 2017 |
|
| Mr Malcolm John McComas | Non-Executive Director | Apr 2019 |
|
| Dr Geoffrey E.D Brooke | Non-Executive Chairman, Non-Executive Director | Mar 2017 |
|
| Dr John (Bill) William Ketelbey | Chief Executive Officer, Managing Director | Dec 2014 |
|
Director Transactions
ACW directors must report any change in shareholding to the ASX within 5 business days.
See Director Transactions for all ASX companies.
| Date | Director | Type | Amount | Price | Value | Notes |
|---|---|---|---|---|---|---|
| 17/11/20 | George Morstyn | Issued | 40,000 | $0.022 | $880 | Rights issue. |
| 17/11/20 | Malcolm McComas | Issued | 100,000 | $0.022 | $2,200 | Rights issue. |
| 17/11/20 | Geoffrey Brooke | Issued | 265,000 | $0.022 | $5,830 | Rights issue. |
| 17/11/20 | John (Bill) Ketelbey | Issued | 128,579 | $0.022 | $2,828 | Rights issue. |
| 17/11/20 | John (Bill) Ketelbey | Issued | 1,862,182 | $0.022 | $40,968 | Rights issue. |
| 31/01/20 | John (Bill) Ketelbey | Cancelled | 3,000,000 | $0.035 | $105,000 | Cancellation of securities. |
| 22/11/19 | John (Bill) Ketelbey | Transfer | 9,000,000 | $0.050 | $450,000 | As advised by the company. |
| 12/04/19 | Malcolm McComas | Issued | 3,000,000 | $0.052 | $156,000 | Issue of options. |
| 13/12/18 | George Morstyn | Issued | 1,500,000 | $0.048 | $72,000 | Issue of options. |
| 13/12/18 | Geoffrey Brooke | Issued | 4,900,000 | $0.048 | $235,200 | Issue of options. |
| 13/12/18 | John (Bill) Ketelbey | Issued | 11,700,000 | $0.048 | $561,600 | Issue of options. |
| 13/07/18 | Geoffrey Brooke | Issued | 300,000 | $0.050 | $15,000 | Participation in share purchase plan. |
| 13/07/18 | John (Bill) Ketelbey | Issued | 300,000 | $0.050 | $15,000 | Participation in share purchase plan. |
| 01/06/18 | George Morstyn | Buy | +200,000 | $0.051 | $10,282 | On-market trade. |
| 22/01/18 | Geoffrey Brooke | Issued | 625,000 | $0.040 | $25,000 | Placement. |
| 22/01/18 | Geoffrey Brooke | Issued | 312,500 | $0.041 | $12,812 | Placement. |
| 21/12/17 | Geoffrey Brooke | Issued | 53,333 | $0.044 | $2,346 | Issue of options. |
| 21/12/17 | Jason Loveridge | Issued | 3,716,677 | $0.044 | $163,533 | Issue of options. |
| 21/12/17 | John (Bill) Ketelbey | Issued | 1,647,172 | $0.044 | $72,475 | Issue of options. |
| 06/07/17 | Anton Uvarov | Transfer | 187,244 | $0.061 | $11,473 | Off-market transfer. |
| 29/03/17 | Geoffrey Brooke | Buy | +400,000 | $0.066 | $26,521 | On-market trade. |
| 24/03/17 | Geoffrey Brooke | Issued | 5,000,000 | $0.060 | $300,000 | Issue of securities. |
| 24/12/15 | John (Bill) Ketelbey | Buy | +10,909 | $0.058 | $629 | |
| 20/05/15 | John (Bill) Ketelbey | Issued | 157,894 | $0.095 | $15,000 | |
| 20/05/15 | Jason Loveridge | Issued | 157,894 | $0.095 | $15,000 | |
| 20/05/15 | Anton Uvarov | Issued | 157,894 | $0.095 | $15,000 | |
| 20/05/15 | Martin Rogers | Issued | 157,894 | $0.095 | $15,000 | |
| 01/12/14 | Anton Uvarov | Buy | +2,000,000 | $0.020 | $40,000 | |
| 01/12/14 | Brendan de Kauwe | Buy | +2,500,000 | $0.020 | $50,000 | |
| 12/12/13 | Daniel Parasiliti | Issued | 1,000,000 | $0.010 | $10,000 | |
| 12/12/13 | Brendan De Kauwe | Issued | 2,000,000 | $0.010 | $20,000 | |
| 09/07/13 | Zhukov (Zeke) Pervan | Buy | +66,666 | $0.021 | $1,381 | |
| 02/07/13 | Zhukov (Zeke) Pervan | Transfer | 9,333 | $1.000 | $9,333 | |
| 02/07/13 | Zhukov (Zeke) Pervan | Transfer | 933,334 | $0.010 | $9,333 | |
| 19/06/13 | Zhukov (Zeke) Pervan | Transfer | 5,666,666 | $0.019 | $107,666 | |
| 19/06/13 | David Zohar | Buy | +221,830 | $0.019 | $4,214 | |
| 08/04/13 | David Zohar | Buy | +142,017 | $0.023 | $3,266 | |
| 02/04/13 | David Zohar | Buy | +20,000 | $0.022 | $440 | |
| 02/04/13 | David Zohar | Expiry | 11,750,000 | $0.021 | $246,750 |
Shareholder Distribution
| Holding Size | 1 - 1,000 | 1,001 - 5,000 | 5,001 - 10,000 | 10,001 - 100,000 | 100,001 and over | Total Shareholders |
|---|---|---|---|---|---|---|
| No. of Shareholders | 58 | 92 | 225 | 1,562 | 1,031 | 2,968 |
Top 20 Shareholders
| Name | Shares | Capital |
|---|---|---|
| HSBC Custody Nominees (Australia) Limited | 227,303,623 | 20.36% |
| Edinburgh Technology Fund Limited | 48,147,864 | 4.31% |
| Surfit Capital Pty Ltd | 30,000,000 | 2.69% |
| Tisia Nominees Pty Ltd (Henderson Family A/C) | 27,867,184 | 2.50% |
| Mrs Sarah Cameron | 25,916,573 | 2.32% |
| Brazil Farming Pty Ltd | 15,000,000 | 1.34% |
| Citicorp Nominees Pty Ltd | 10,604,474 | 0.95% |
| Mr Steven Veronese | 10,008,001 | 0.90% |
| Oaktone Nominees Pty Ltd (Grist Investment A/C) | 10,000,000 | 0.90% |
| Mrs Gillian Karen Nes & Mrs Ronald Nes (Giro S/F A/C) | 9,950,000 | 0.89% |
| Kaleidoscope Holdings Pty Ltd (Kaleidoscope Super A/C) | 9,000,000 | 0.81% |
| Griffin & Grace Investments Pty Ltd (Griffin & Grace Inv S/F A/C) | 8,800,000 | 0.79% |
| Mr Peter James Nixon | 8,400,000 | 0.75% |
| Alua Capital Pty Ltd | 8,000,000 | 0.72% |
| BNP Paribas Nominees Pty Ltd Hub24 Custodial Serv Ltd Drp | 7,738,901 | 0.69% |
| BNP Parabis Nominees Pty Ltd (Bnpp Nyb Clearing Acc Drp) | 7,560,729 | 0.68% |
| Bannaby Investments Pty Ltd (Super Fund A/C) | 7,500,000 | 0.67% |
| Webinvest Pty Ltd (Olsb Unit A/C) | 7,000,000 | 0.63% |
| Romfal Sifat Pty Ltd (The Fizmail Family A/C) | 7,000,000 | 0.63% |
| Paranji Super Fund Pty Ltd (Paranji Superfund A/C) | 6,500,000 | 0.58% |
| All other shareholders | 55.89 % | |
The Top 20 Shareholders of ACW hold 44.11% of shares on issue.
ACW Share Price History
| Date | Close | Change | % Change | Open | High | Low | Volume | Turnover |
|---|---|---|---|---|---|---|---|---|
ACW Historical Data
Download up to 20 years of share price history.
| Year | Closing Price (30 June) | Last Trade |
|---|---|---|
| 2020 | $0.022 | 30 June |
| 2019 | $0.01 | 28 June |
| 2018 | $0.048 | 29 June |
| 2017 | $0.061 | 28 June |
| 2016 | $0.072 | 28 June |
| 2015 | $0.072 | 30 June |
| 2014 | $0.011 | 30 June |
Offical data as published by ASX. See more Data Downloads.
Company Details
Principal Activity: Development of Xanamem, a novel treatment for Alzheimer's disease and the cognitive deficiency associated with other neurological and metabolic diseases.
Incorporated: Actinogen Limited was incorporated on 26/03/1999 in Western Australia.
Suite 901, Level 9, 109 Pitt St
Sydney NSW 2000
All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.